Q&A on Tissue Regenix Group plc: Significan...

Hardman & Co Research Hardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct 11-Aug-2022 / 16:30 GMT/BST Hardman & Co Video | Analyst interview Tissue Regenix Group plc: Significantly undervalued which should correct Tissue Regenix Group plc (TRX) is the topic of conversation when Martin Hall joins DirectorsTalk Interviews. Martin reminds us of what the company does, summrises the key details from its trading update, talks though the implications of a strong sales performance, the key value added in the research report and thoughts on what will happen to the share price. Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative products. Listen to the interview here: If you are interested in meeting the company, you can register your interest here Download our latest report on TRX, here To contact us: Hardman & Co 1 Frederick’s Place London EC2R 8AE www.hardmanandco.com Follow us on Twitter @HardmanandCo Contact: Martin Hall [phone] [e-mail]   Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement. About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report. Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

1419101 11-Aug-2022